Efficient and stable Sendai virus-mediated gene transfer into primate embryonic stem cells with pluripotency preserved

Article metrics


Efficient gene transfer and regulated transgene expression in primate embryonic stem (ES) cells are highly desirable for future applications of the cells. In the present study, we have examined using the nonintegrating Sendai virus (SeV) vector to introduce the green fluorescent protein (GFP) gene into non-human primate cynomolgus ES cells. The GFP gene was vigorously and stably expressed in the cynomolgus ES cells for a year. The cells were able to form fluorescent teratomas when transplanted into immunodeficient mice. They were also able to differentiate into fluorescent embryoid bodies, neurons, and mature blood cells. In addition, the GFP expression levels were reduced dose-dependently by the addition of an anti-RNA virus drug, ribavirin, to the culture. Thus, SeV vector will be a useful tool for efficient gene transfer into primate ES cells and the method of using antiviral drugs should allow further investigation for regulated SeV-mediated gene expression.


Since human embryonic stem (ES) cell lines have the ability to both proliferate indefinitely and differentiate into multiple tissue cells,1, 2 they are expected to have clinical applications as well as to serve as models for basic research and drug development. Although efficient and stable gene transfer into primate ES cells would be useful for such purposes, it has been difficult and only lentiviral vectors have been successful in achieving it.3, 4, 5 We have previously developed Sendai virus (SeV) vectors that replicate in the form of negative-sense single-stranded RNA in the cytoplasm of infected cells and do not go through a DNA phase.6 SeV vectors can efficiently introduce foreign genes without toxicity into airway epithelial cells,7 vascular tissue,8 skeletal muscle,9 synovial cells,10 retinal tissue,11 and hematopoietic progenitor cells.12 Here we report that the SeV-mediated gene transfer into primate ES cells is very efficient and stable even after the terminal differentiation of the cells. In addition, we show that SeV-mediated transgene expression levels can be reduced by the addition of a ribonucleoside analog, ribavirin, to the culture. Ribavirin is a mutagen and inhibitor of viral RNA polymerase.13, 14 It shows antiviral activity against a variety of RNA viruses and is used to treat infections of hepatitis C virus in combination with interferon-α15, 16 and of lassa fever virus.17 The method of using antiviral drugs might offer a novel approach for regulated SeV-mediated gene expression in primate ES cells.


SeV-mediated gene transfer into ES cells

In this study, we have used an SeV vector, which is capable of self-replication but incapable of transmitting to other cells.6 The vector does not encode the fusion (F) protein (Figure 1a), which is essential for viral entry into cells. It can be propagated only in a packaging cell line expressing the F protein. The green fluorescent protein (GFP) gene was introduced after the leader sequence of the vector genome. Cynomolgus ES cells18 were exposed to the SeV vector for 24 h. Flow cytometric analysis at 2 days after infection showed that 15, 38, and 61% of cells fluoresced at 2, 10, and 50 transducing units (TU) per cell, respectively (Figure 1b). The gene transfer efficiency of about 60% is comparable to or even better than that for lentiviral vectors.3 We confirmed that the undifferentiated cell fractions remained unchanged after the infection with SeV vector, as assessed by the expression of undifferentiated markers, alkaline phosphatase and SSEA-4 (data not shown). The GFP expression after infection was stable at least for a month. On the other hand, the GFP gene transfer to cynomolgus ES cells with adenovirus- and adeno-associated virus (AAV)-based vectors resulted in much lower expression levels (<20% by flow cytometry) and the levels declined to zero within a week after infection (Figure 1c).

Figure 1

High-level transgene expression in cynomolgus ES cells after infection with SeV vector. (a) Schematic diagrams of the wild-type SeV genome and recombinant F-defective SeV carrying the GFP gene (SeV vector in this study). The SeV genome is 15 384 nucleotides long and its genes (NP, P, M, F, HN, and L) are in order from 3′ to 5′ in the negative-strand RNA. In the SeV vector, the entire fusion (F) gene was removed and the GFP gene was introduced at a unique NotI site between the leader sequence and NP gene. (b) The GFP expression by the SeV vector in cynomolgus ES cells. Cynomolgus ES cells were infected with the SeV vector at 2, 10, and 50 TU/cell. The flow cytometric profiles at day-2 postinfection are shown in gray. The white areas indicate uninfected ES cells. The fractions of GFP-positive cells are indicated. (c) The GFP expression levels in cynomolgus ES cells infected with the SeV (50 TU/cell), adenovirus serotype 5 (Ad5, 3.4 × 102 g.c./cell), and AAV serotype 2 (AAV2, 2.4 × 104 g.c./cell) vectors. The fractions of GFP-positive cells were examined by flow cytometry at 2, 4, and 7 days postinfection.

We plucked fluorescent ES cell colonies under a fluorescent microscope once at 1 month after infection and propagated them. After this selection procedure, approximately 90% of the ES cells expressed GFP (Figure 2a and b) and the high-level expression was stable for a year as assessed by flow cytometry (Figure 2c, upper). The mean fluorescence intensity per cell was also stable (Figure 2c, lower), indicating that the replicating vector genome was almost equally delivered to each cell of all progeny. The self-replication of the SeV vector in infected cells was confirmed by RNA-PCR that amplified the viral RNA genomic sequence (Figure 3a). The GFP cDNA sequence, however, could not be detected by DNA-PCR in the infected cells (Figure 3b), indicating that no DNA phase was involved in the GFP expression.

Figure 2

Stable SeV-mediated transgene expression in cynomolgus ES cells. Fluorescent ES cell colonies were plucked under a fluorescent microscope once at 1 month after infection and the cells were further propagated. (a) Phase-contrast (upper) and fluorescence (lower) images of a cynomolgus ES cell colony at day 370 after infection. Bar=100 μm. (b) Flow cytometric analysis of SeV-infected cynomolgus ES cells at day 370 after infection (shown in green). The percentage of GFP-positive cells is indicated. Uninfected, parental cynomolgus ES cells are indicated by another line (white area). (c) The percentage of GFP-positive cells (upper) and mean fluorescence intensity per GFP-positive cell (lower) after infection with the SeV vector at 10 TU/cell are shown as a function of time (days).

Figure 3

DNA-independent replication and transcription of SeV vector. Total cellular RNA and DNA were extracted from cynomolgus ES cells at day 284 after infection with the SeV vector. RNA-PCR (a) and DNA-PCR (b) for the SeV RNA genome or GFP sequence were conducted. The cynomolgus β-actin sequence was used as an internal control. In the RNA-PCR (a), negative results obtained without reverse transcriptase (designated RT−) confirmed that the amplified products were not derived from cellular DNA. M, 100-kb DNA ladder; cES, naive cynomolgus ES cells; cES/Transfectant, cynomolgus ES cells stably expressing the GFP gene after transfection,33 cES/SeV, cynomolgus ES cells infected with the SeV vector; wtSeV, wild-type SeV genome; mTransfectant, a GFP-positive mouse cell line after transfection.

Pluripotency of infected ES cells

The SeV-infected, fluorescent cynomolgus ES cells were able to form fluorescent tumors when transplanted into immunodeficient mice (Figure 4a–c). The fluorescence was observed uniformly by fluorescent microcopy (Figure 4d and e). The tumors consisted of all three embryonic germ layer cells (Figure 4f–i). Thus, the SeV-infected ES cells were capable of forming teratomas and the SeV infection did not spoil the pluripotency of ES cells. The infected, fluorescent cynomolgus ES cells were also able to generate fluorescent embryoid bodies (Figure 5a and b), MAP-2-positive neurons (Figure 5c), clonogenic hematopoietic colonies (Figure 5d and e), and mature functional (NBT test-positive) neutrophils (Figure 5f and g), all of which fluoresced. In addition, the GFP expression levels were not decreased during the teratoma formation or differentiation, indicating that no ‘silencing’ of the transgene occurred.

Figure 4

Pluripotency of SeV-infected cynomlgus ES cells. Tumors formed in NOD-SCID mice after inoculation of the SeV-infected cynomolgus ES cells (a). The tumor was fluorescing ((b), bright field; (c), dark field). Fluorescence was observed uniformly in the tumor under a fluorescent microscope ((d), bright field; (e), dark field). The tumor contained all three embryonic germ layer cells; cartilage (f), ciliated columnar epithelium (g), skin (h), and sebaceous gland (i) (stained with hematoxylin and eosin). Bar=100 μm.

Figure 5

Stable transgene expression during differentiation. A day-20 cystic embryoid body was observed under a fluorescent phase-contrast microscope, confirming that the embryoid body was fluorescing ((a), bright field; (b), dark field). After infection with the SeV vector, fluorescent cynomolgus ES cells differentiated into neural cells. Double immunostaining with anti-GFP (green) and ant-MAP-2 (red) confirmed that differentiated neural cells expressed GFP (c). Yellow cells indicate GFP-expressing neurons. SeV-infected, fluorescent cynomolgus ES cells also differentiated into fluorescent hematopoietic cells. A clonogenic hematopoietic colony was fluorescing ((d) bright field; (e), dark field). A cytospin specimen of hematopoietic colony cells (Wright–Giemsa staining) showed that the cells were mature granulocytes (f). The infected ES cell-derived, fluorescent neutrophils were positive for NBT (stained in black (g)). Bar=100 μm (a, b, g); 50 μm (c, f); 500 μm (d, e).

Drug-inducible reduction of transgene expression

Next, we examined whether ribavirin inhibits the replication and transcription of the SeV vector resulting in a reduction of transgene expression. We first used a rhesus monkey kidney cell line (LLC-MK2) to test the effect of ribavirin on the replication and transcription of the SeV vector. LLC-MK2 is a standard control cell line for SeV infection. Ribavirin was added at various concentrations 2 days after the infection. The formation of viral particles quantified by the hemagglutination assay decreased drastically upon the addition of ribavirin (Figure 6a). The decrease was dependent on the dose of ribavirin. The GFP expression was also depressed dose-dependently (Figure 6b). Thus, ribavirin dose-dependently inhibits the replication and transcription of the SeV vector in LLC-MK2 cells. The toxicity associated with ribavirin was not observed in LLC-MK2 cells.

Figure 6

Ribavirin-regulated transgene expression. (a) A rhesus kidney cell line (LLC-MK2) was infected with the SeV vector at 3 TU/cell. Ribavirin was started at various concentrations on day 2 after the infection. The formation of viral particles in the infected LLC-MK2 cells was examined by the hemagglutination assay. (b) The ribavirin-treated LLC-MK2 cells were observed under a fluorescent microscope after an 8-day exposure of ribavirin (upper, dark field; lower, bright field). (c) Ribavirin was added at various concentrations to the SeV-infected, fluorescent cynomolgus ES cells. The GFP expression was assessed by flow cytometry after a 3-day exposure of ribavirin. (d) The fractions of SSEA-4-positive ES cells were assessed by flow cytometry with anti-SSEA-4 before and after a 3-day exposure of ribavirin and are shown as a function of time (days) in the left panel. A gray bar indicates ribavirin treatment. ES cells were stained for alkaline phosphatase (in red) at day 21 after a 3-day exposure of 0.75 mM ribavirin and are shown in the right panel. Bar=100 μm.

We then examined the effect of ribavirin on SeV-infected, fluorescent cynomolgus ES cells. The addition of ribavirin also resulted in a dose-dependent reduction of GFP expression in the cells (Figure 6c). Although the GFP expression was almost completely inhibited after a 3-day exposure with 4 mM of ribavirin, the cells could not be propagated thereafter. Ribavirin at high concentrations (>1 mM) hampered the proliferation of cynomolgus ES cells. With lower concentrations (0.5–0.75 mM) of ribavirin, the GFP expression level decreased by half. After the discontinuation of ribavirin treatment, the cells could be propagated and nearly regained the original level of GFP expression. The undifferentiated cell fractions were unchanged after the discontinuation as assessed by alkaline phosphatase and SSEA-4 staining (Figure 6d).


There are several advantages in using SeV vectors over other vectors. (i) SeV vectors can infect nondividing, quiescent cells as well as dividing cells unlike oncoretroviral vectors.7, 8, 9, 10, 11 Thus, they can be used to infect cells that are terminally differentiated as well as at various stages of differentiation, whether they are dividing or not. (ii) SeV vector-mediated gene transfer does not require a DNA phase. Thus, there is no concern about the unwanted integration of foreign sequences into the host genome unlike with oncoretroviral or lentiviral vectors. (iii) Transgene expression is stable even in dividing cells since the SeV vector replicates by itself in the cytoplasm of host cells. On the other hand, gene transfer using nonreplicating adenoviral and AAV vectors resulted in decreased levels of transgene expression in dividing cells over time, since the non-replicating transgene was diluted out. (iv) The SeV vector is much less unlikely to generate wild-type virus in vitro or in vivo than oncoretroviral and lentiviral vectors, since homologous recombination between RNA genomes is very rare indeed in negative-strand RNA viruses.19 (v) The SeV genome is not subject to cellular epigenetic modifications such as methylation, and thus it is unlikely that methylation-based silencing of transgene expression occurs.

No cytotoxic or differentiating effect on ES cells associated with the SeV infection was observed in our study. However, the wild-type SeV contains immunogenic surface proteins, hemagglutinin-neuraminidase (HN) and F proteins, which potentially induce antibody responses.20, 21 For future clinical applications, it would be desired that as many viral genes as possible are deleted from the vector backbone to permit reapplication, improve the safety, and lessen the possible toxicity of SeV vectors. To this end, we have developed a series of attenuated SeV vectors that are F gene-deleted,6 F gene-deleted with preferable mutations,22 M gene-deleted,23 or have deletions of both F and M genes.24 The modified vectors would be safer for in vivo use.

Ribavirin at high concentrations seems toxic to ES cells; presumably, it directly hampers viability and proliferation potential of ES cells. However, we cannot tell whether the observed toxicity is simply due to its toxicity to ES cells, as feeder cells are more highly sensitive to ribavirin than ES cells. In fact, while feeder cells died at 1 mM of ribavirin, cocultured ES cells were alive at this concentration for some time. Cynomolgus ES cells lose pluripotency and proliferation potential without feeder cells. Thus, the observed toxicity to ES cells may also be a secondary event following the injury of feeder cells. Whether the cytotoxicity is primary or secondary, it will be necessary to find modified compounds of less cytotoxicity.

Materials and methods

Cell culture

Cynomolgus ES cells (CMK6) were maintained on a feeder layer of mitomycin C (Kyowa, Tokyo, Japan)-treated mouse (BALB/c) embryonic fibroblasts as described previously.18 The culture medium consisted of Dulbecco's modified Eagle's medium (DMEM)/F12 (Invitrogen, Carlsbad, CA, USA) supplemented with 15% ES cell-qualified fetal calf serum (FCS; Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma, St Louis, MO, USA), 2 mM glutamine (Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin, Irvine Scientific, Santa Ana, CA, USA). The ES cell colonies were routinely passaged every 3–4 days after dissociation with a combined approach of 0.25% trypsin (Invitrogen) digestion and mechanical cutting. Alkaline phosphatase staining was conducted with an Alkaline Phosphatase Chromogen Kit (Biomeda, Foster City, CA, USA). Embryoid bodies were produced by culturing ES cell aggregates in Petri dishes. LLC-MK2 cells (1 × 106) were grown in six-well plates and cultured in Eagle's minimal essential medium (Invitrogen) supplemented with 10% FCS.


The F-defective SeV vector carrying the GFP gene was constructed as previously described.6 The vector titer was 1.8 × 109 TU/ml determined by counting fluorescent cells after the infection of LLC-MK2 cells. Gene transfer was conducted by adding various concentrations of the SeV vector solution to culture media. After 24 h of incubation, the cells were washed twice with phosphate-buffered saline (PBS) and fresh medium was added. In some experiments, ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; Sigma) was added at various concentrations to the culture media after infection. The viral particles in infected cells were quantified by a hemagglutination assay as described previously.25

An adenovirus serotype 5-based vector carrying the GFP gene was constructed as reported.26 It contained the cytomegalovirus (CMV) promoter, simian virus (SV)-40 intron, and SV-40 polyadenylation signal. An AAV serotype 2-based vector expressing the GFP gene under the control of the chicken β-actin promoter with the CMV immediate-early enhancer (a gift from Dr J Miyazaki) was prepared as described previously.27 Gene transfer experiments were performed using 3.4 × 102 genome copies (g.c.)/cell of the adenoviral vector or 2.4 × 104 g.c./cell of the AAV vector. The period of exposure was 48 h.

Flow cytometry

GFP and SSEA-4 expression was analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA) using the CellQuest software (Becton Dickinson). For SSEA-4 staining, cells were incubated with a primary antibody, anti-SSEA-4 (MC-813-70; Chemicon, Temecula, CA, USA), and then a secondary antibody, PE-conjugated F(ab′)2 fragment of rabbit anti-mouse immunoglobulins (DakoCytomation, Glostrup, Denmark). Cocultured BALB/c feeder cells could be distinguished from cynomolgus ES cells by using PE-conjugated anti-mouse H-2d (SF1-1.1; PharMingen, San Diego, CA, USA), which does not react to cynomolgus cells but does react to BALB/c cells.

Teratoma formation

Cynomolgus ES cells (approximately 106 cells per site) were injected subcutaneously into the hind leg of 6- to 8-week-old nonobese diabetic/severe combined immunodeficient mice (Jackson Laboratory, Bar Harbor, ME, USA). The resulting tumors (usually 9–12 weeks after the injection) were dissected and fixed in 4% paraformaldehyde. For histological analysis, samples from the tumors were embedded in paraffin and stained with hematoxylin and eosin. To observe GFP fluorescence, samples were embedded in OTC compound (Sakura, Zoeterwoude, Netherlands), frozen, sectioned, and examined under a fluorescence microscope.

Hematopoietic differentiation

The mouse bone marrow stromal cell line OP9 was maintained in α-modified minimum essential medium (Invitrogen) supplemented with 20% FCS as described previously.28 For induction of hematopoietic differentiation, ES cells were seeded onto a mitomycin C-treated confluent OP9 cell layer in six-well plates. Medium to support the differentiation was described elsewhere.29 Cells at day 18 were placed in Methocult GF+ media (StemCell Technologies, Vancouver, Canada) at 1 × 104 and 1 × 105 cells per plate and clonogenic hematopoietic colonies were produced. After 14 days, individual colonies were removed and spun onto glass slides. Cells were stained with the Wright–Giemsa method. The nitro blue tetrazolium (NBT, Sigma) reduction test was performed on the cells as a granulocyte functional assay according to a previously described method.30

Neural differentiation

The induction of neural differentiation was carried out as described previously.31 Day-4 embryoid bodies were plated onto tissue culture dishes and nestin-positive cells were selected in DMEM/F12 medium supplemented with 5 μg/ml of insulin (Sigma), 50 μg/ml of transferrin (Sigma), 30 nM selenium chloride (Sigma), and 5 μg/ml of fibronectin (Sigma) for 5 days. Cells were then trypsinized and plated in polyornithine-coated dishes (15 μg/ml) and expanded in N2 medium32 supplemented with 1 μg/ml of laminin (Sigma) and 10 μg/ml of basic fibroblast growth factor (bFGF; Roche, Basel, Switzerland) for 6 days. Differentiation was induced by removal of bFGF. To confirm the neural differentiation, cells were stained with anti-human MAP-2. Briefly, cells were fixed in 4% paraformaldehyde in PBS and incubated with anti-human MAP-2 (HM-2; Sigma; diluted 1:4000) and then by Alexa Fluor 594-labeled antibody (diluted 1:500; Molecular Probe, Eugene, OR, USA). The samples were examined under a fluorescence microscope.


DNA-PCR for the SeV genome and GFP sequences was carried out as follows. DNA was extracted using the QIAamp DNA mini kits (Qiagen, Hilden, Germany) and 250 ng was used for each PCR with ExTaq (Takara, Shiga, Japan). Amplification conditions were 30 cycles of 94°C for 1 min, a variable annealing temperature (noted below) for 1 min, and 72°C for 1 min. The amplified products were run on 2% agarose gel and visualized by ethidium bromide staining. Primer sequences, annealing temperatures and product sizes were as follows: the SeV vector genome sequence: 5′-IndexTermAGA GAA CAA GAC TAA GGC TAC C-3′ and 5′-IndexTermACC TTG ACA ATC CTG ATG TGG-3′ (55°C, 580 bp); the GFP sequence: 5′-IndexTermCGT CCA GGA GCG CAC CAT CTT C-3′ and 5′-IndexTermGGT CTT TGC TCA GGG CGG ACT-3′ (60°C, 356 bp). the cynomolgus β-actin sequence: 5′-IndexTermCAT TGT CAT GGA CTC TGG CGA CGG-3′ and 5′-IndexTermCAT CTC CTG CTC GAA GTC TAG GGC-3′ (60°C, 234 bp).


RNA-PCR for the SeV RNA genomic sequence was carried out as follows. Total RNA was extracted using RNA STAT-60 (Tel-Test, Friendswood, TX, USA). Reverse transcription was conducted by using Taqman reverse transcription reagents (Applied Biosystems, Foster City, CA, USA). The product (250 ng) after the reverse transcription was used for the subsequent PCR as described above.


  1. 1

    Thomson JA et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145–1147.

  2. 2

    Reubinoff BE et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000; 18: 399–404.

  3. 3

    Asano T et al. Highly Efficient gene transfer into primate embryonic stem cells with a simian lentivirus vector. Mol Ther 2002; 6: 162–168.

  4. 4

    Ma Y et al. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 2003; 21: 111–117.

  5. 5

    Gropp M et al. Stable genetic modification of human embryonic stem cells by lentiviral vectors. Mol Ther 2003; 7: 281–287.

  6. 6

    Li HO et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74: 6564–6569.

  7. 7

    Yonemitsu Y et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970–973.

  8. 8

    Masaki I et al. Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system. FASEB J 2001; 15: 1294–1296.

  9. 9

    Shiotani A et al. Skeletal muscle regeneration after insulin-like growth factor I gene transfer by recombinant Sendai virus vector. Gene Therapy 2001; 8: 1043–1050.

  10. 10

    Yamashita A et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002; 168: 450–457.

  11. 11

    Ikeda Y et al. Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure. Exp Eye Res 2002; 75: 39–48.

  12. 12

    Jin CH et al. Recombinant Sendai virus provides a highly efficient gene transfer into human cord blood-derived hematopoietic stem cells. Gene Therapy 2003; 10: 272–277.

  13. 13

    Crotty S et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375–1379.

  14. 14

    Vo NV, Young KC, Lai MM . Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 2003; 42: 10462–10471.

  15. 15

    McHutchison JG et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–1492.

  16. 16

    Davis GL et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–1499.

  17. 17

    McCormick JB et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20–26.

  18. 18

    Suemori H et al. Establishment of embryonic stem cell lines from cynomolgus monkey blastocysts produced by IVF or ICSI. Dev Dyn 2001; 222: 273–279.

  19. 19

    Spann KM, Collins PL, Teng MN . Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol 2003; 77: 11201–11211.

  20. 20

    Tozawa H et al. Neutralizing activity of the antibodies against two kinds of envelope glycoproteins of Sendai virus. Arch Virol 1986; 91: 145–161.

  21. 21

    Tashiro M, Tobita K, Seto JT, Rott R . Comparison of protective effects of serum antibody on respiratory and systemic infection of Sendai virus in mice. Arch Virol 1989; 107: 85–96.

  22. 22

    Inoue M et al. Nontransmissible virus-like particle formation by F-deficient Sendai virus is temperature sensitive and reduced by mutations in M and HN proteins. J Virol 2003; 77: 3238–3246.

  23. 23

    Inoue M et al. A new Sendai virus vector deficient in the matrix gene does not form virus particles and shows extensive cell-to-cell spreading. J Virol 2003; 77: 6419–6429.

  24. 24

    Inoue M et al. Recombinant Sendai virus vectors deleted in both the matrix and the fusion genes: efficient gene transfer with preferable properties. J Gene Med, published online 5 May 2004. doi:10.1002/jgm.597.

  25. 25

    Kato A et al. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1996; 1: 569–579.

  26. 26

    Okada T et al. Efficient directional cloning of recombinant adenovirus vectors using DNA–protein complex. Nucleic Acids Res 1998; 26: 1947–1950.

  27. 27

    Okada T et al. Adeno-associated viral vector-mediated gene therapy of ischemia-induced neuronal death. Methods Enzymol 2002; 346: 378–393.

  28. 28

    Nakano T, Kodama H, Honjo T . Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science 1994; 265: 1098–1101.

  29. 29

    Li F et al. Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro. Blood 2001; 98: 335–342.

  30. 30

    Sekhsaria S et al. Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease. Proc Natl Acad Sci USA 1993; 90: 7446–7450.

  31. 31

    Lee SH et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000; 18: 675–679.

  32. 32

    Johe KK et al. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 1996; 10: 3129–3140.

  33. 33

    Takada T et al. Monkey embryonic stem cell lines expressing green fluorescent protein. Cell Transplant 2002; 11: 631–635.

Download references


Cynomolgus ES cells were provided by Norio Nakatsuji (Kyoto University, Kyoto, Japan), Yasushi Kondo (Tanabe Seiyaku Co. Ltd, Osaka, Japan), and Ryuzo Torii (Shiga University of Medical Science, Shiga, Japan). OP9 cells were provided by Toru Nakano (Osaka University, Osaka, Japan). We thank Yujiro Tanaka and Takayuki Asano for cultivating cynomolgus ES cells and Takeshi Hara for conducting NBT tests. We also thank Natsuko Kurosawa for technical assistance.

Author information

Correspondence to Y Hanazono.

Rights and permissions

Reprints and Permissions

About this article


  • primate embryonic stem cell
  • Sendai virus vector
  • gene transfer
  • green fluorescent protein
  • pluripotency
  • ribavirin

Further reading